Agios Pharmaceuticals (AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to less than18 years with PK ...

Agios' mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing application based on the results.

Cash, cash equivalents and marketable securities as of December 31, 2024, were $1.5 billion compared to $806.4 million as of December 31, 2023.

Discover Agios Pharmaceuticals' Q4 2024 earnings highlights, growth plans for Pyrukynd in thalassemia & sickle cell, and insights on safety, clinical ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

KBC Group NV lifted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 30.5% during the fourth quarter, according to the company in its most recent filing with the SEC.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a biopharmaceutical company focused on cellular metabolism to treat cancer and rare genetic diseases, announced the upcoming departure of a key board member.

Theodore James Jr. Washburn, the Principal Accounting Officer at Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), recently sold 2,272 shares of common stock. The shares were sold at a price of $34.39 each, ...

CAMBRIDGE, MA—Theodore James Jr. Washburn, the Principal Accounting Officer at Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), recently sold 2,272 shares of common stock. The shares were sold at a ...

The stock has a market cap of $1.85 billion, a P/E ratio of 2.85 and a beta of 0.87. Agios Pharmaceuticals has a 1-year low of $20.96 and a 1-year high of $62.58. In other Agios Pharmaceuticals ...

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare ...